测试版
试验雷达 AI
临床试验 NCT06853015 针对脊髓损伤 (SCI)目前招募中。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情,或在此提出任何问题。
一个试验符合筛选条件
卡片视图

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

招募中
临床试验详情主要以英语提供。然而,试验雷达 AI可以提供帮助!只需点击“解释临床试验”即可查看和讨论您选择的语言的试验信息。
临床试验NCT06853015旨在研究治疗,主要针对脊髓损伤 (SCI)。这是一项I期 (第一期) II期 (第二期) 干预性研究试验,目前试验状态为招募中。试验始于2025年2月1日,计划招募27名患者。该研究由Shirley Ryan AbilityLab主导,预计于2026年3月1日完成。试验数据来源于ClinicalTrials.gov,最后更新时间为2025年4月3日
简要概括
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
详细描述
Currently, research has shown that 4-AP has a positive effect on sensory and motor function rehabilitation in humans with chronic SCI in addition to decreasing recorded spasticity, increased sensation, and decreased pain. A pharmacokinetic study showed that twice-daily administration of sustained release 4-AP maintains a steadier plasma concentration. Utilizing limb training to promote recovery of motor function is enhanced by eliciting STDP in the limbs. An important strength of this aim is the combination of training and STDP, which aims to enhance the beneficial effects of motor training by promoting plasticity in the corticospinal pathway. Training effects on physiological pathways will be explored and correlated with lower limb motor function. We hypothesize that introducing 4-AP into the STDP stimulation and STDP stimulation with training will further improve motor function rehabilitation in patients with chronic SCI.
官方标题

Effects of Twice-daily Dosing 4-AP on Functional Recovery After Spinal Cord Injury

疾病
脊髓损伤 (SCI)
其他研究标识符
  • STU00221545
NCT编号
实际开始日期
2025-02-01
最近更新发布
2025-04-03
预计完成日期
2026-03
计划入组人数
27
研究类型
干预性研究
试验分期 (阶段)
I期 (第一期)
II期 (第二期)
试验状态
招募中
关键词
spinal cord injury
neurostimulation
4-AP
rehabilitation
主要目的
治疗方法
分配方式
随机
干预模型
平行
盲法
三盲
试验组/干预措施
参与者组/试验组干预措施/治疗方法
实验性4-AP(AM) + STDP stimulation + training + 4-AP(PM)
The effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of twice-daily-dosing 4-AP, STDP stimulation and training.
Dalfampridine
The study drug (4-AP) will be administered as a 10 mg dose twice a day.
STDP Stimulation
Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
运动训练
Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
安慰剂对照Placebo(AM) + STDP stimulation + training + Placebo(PM)
The effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of twice-daily-dosing Placebo, STDP stimulation and training.
安慰剂
The placebo provided by the SRAL pharmacy that looks identical to the 4-AP, will be administered twice a day.
STDP Stimulation
Paired stimulation will be given to the spinal cord and to peripheral nerves so that the signals are received at the spinal cord at a specific interval.
运动训练
Lower-limb exercises will involve over-ground walking, treadmill, walking and stair climbing training.
主要终点
结果指标度量标准描述时间框架
Change in TMEPs
Electrical stimulation will be performed placing the cathode on the upper thoracic between the spinal processes between T3 and T4 vertebrae and the anode at \~10 cm above
TMEPs measured at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
Change in MVC
Individuals will perform a maximum voluntary contraction (MVC) of each targeted muscle (quadriceps femoris, tibialis anterior or soleus) through surface electrodes secured to the skin over the belly of each muscle. Ankle flexion torque will be measured by measured by force sensors.
MVC measured at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
次要终点
结果指标度量标准描述时间框架
Change in 10-meter walk test
We will use the 10-meter walk test to quantify walking speed in meters per second. The same percentage of body-weight support will be used during pre- and post-assessments. Less time to walk 10-meter indicates better outcome.
10-m walk measured at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
Change in 6-minute walk test
We will measure the distance walked over 6 minutes. The same percentage of body-weight support will be used as in 10-meter walk test. The longer distance walked during 6 minutes indicates better outcome.
6-min walk measured at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
Change in International Standards for Neurological Classification of Spinal Cord Injury exam
Motor part of the exam is completed through the testing of key muscle functions corresponding to 10 myotomes (C5-T1 and L2-S1) for right and left side separately. The strength of each muscle function is graded on a six-point scale ranging from 0 meaning complete paralysis to 5 meaning full strength. The total motor score is sum of all motor scores range from 0-100. Sensory part of the exam is completed through the testing of a key point in each of the 28 dermatomes (from C2 to S4-5) on the right and left sides of the body. At each of these key points, two aspects of sensation are examined: light touch and pin prick. Appreciation of light touch and pin prick sensation at each of the key points is separately scored on a three-point scale; 0-absent, 1-altered, and 2-normal or intact. 56 is the maximum score for both light touch and pin prick and the total sensory score ranges from 0 to 112. Higher scores represent better outcome for motor and sensory scores.
Scores measured at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
Change in EPT
We use electrical perceptual threshold (EPT) to measures the minimum amount of electrical current that the participant can perceive when applied to the lower limb dermatomes (L2-S2).
EPT will be measured at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
Change in surveys on ambulation, basic mobility, bowel and bladder management difficulties
The name of the questionnaire is Spinal Cord Injury Quality of Life (SCI-QOL) and we used four subdomains: ambulation, self-care, bowel management difficulties, and bladder management difficulties. Scores on all subdomains of SCI-QOL use a standardized T metric, with a mean of 50 and a standard deviation of 10. Ambulation and basic mobility subdomains assess the ability to engage in walking activities in different locations that vary based on speed, time and condition and the ability to manage stairs under different conditions. Bowel management difficulties subdomain measures an ability to carry out a bowel program; concerns about incontinence and bowel accidents; and the impact of bowel management on everyday living. Bladder management difficulties subdomain measures ability to carry out a bladder program; worry about bladder accidents; concerns about implementing one's bladder program; and impact on everyday living. Higher scores on all subdomains represent better outcome.
SCI-QOL measured at at baseline, at 6 weeks (post 20 sessions), and at 12 weeks (post 40 sessions).
Change in morphological characterization of corticospinal and reticulospinal pathways in MRI
In order to identify descending motor tract, brainstem and C2 cervical spinal cord images will be acquired on a MAGNETOM Prisma 3T system using a 64-channel birdcage head/neck coil. To quantify the effect of atrophy in oblique directions, we will measure the radius from the cord shape center of mass to its border, R(α), for angles α over the whole circle with an angular resolution of 6°. Mean measures of all 5 axial slices will be used for statistical from nerve roots, noise, and other confounding effects.
MRI measured at baseline, and at 12 weeks (post 40 sessions).
资格标准

适龄参与研究
成人, 老年人
最低年龄要求
18 Years
适龄性别
全部
  • Male and females between ages 18-85 years
  • SCI 6 months post injury
  • Spinal Cord injury at or above L2
  • ASIA A, B, C, or D, complete or incomplete
  • The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles

  • Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease
  • Any history of renal impairment
  • Any debilitating disease prior to the SCI that caused exercise intolerance
  • Premorbid, ongoing major depression or psychosis, altered cognitive status
  • History of head injury or stroke
  • Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
  • History of seizures or epilepsy
  • Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)
  • Pregnant females
  • If a women of child bearing age is unsure of the pregnancy, and does not want to take the pregnancy test
  • Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk
  • Metal plate in skull
  • Individuals with scalp shrapnel, cochlear implants, or aneurysm clips
  • Individuals taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or PR Interval prolonging drugs
Shirley Ryan AbilityLab logoShirley Ryan AbilityLab
研究责任方
Monica Perez, 主要研究者, Scientific Chair, Shirley Ryan AbilityLab
研究中心联系人
联系人: Monica Perez, PT, PhD, 312-238-2886, [email protected]
联系人: Bing Chen, PhD, 312-238-7895, [email protected]
1 位于 1 个国家/地区的研究中心

Illinois

Shirley Ryan Abilitylab, Chicago, Illinois, 60611, United States
Monica Perez, PT, PhD, 联系人, 312-238-2886, [email protected]
招募中